Kerri Fitzgerald
Articles by Kerri Fitzgerald
The FDA approves the first bispecific antibody for relapsed/refractory DLBCL.
The FDA approved the first and only noncovalent BTK inhibitor for MCL.
Race/ethnicity, income, and access to chemotherapy and radiation therapy improved outcomes in patients with Burkitt lymphoma.
The cell of origin in patients with diffuse large B-cell lymphoma may impact their response to CAR-T therapy and survival.
Mutation of CALR in patients with myelofibrosis may be associated with a more anemic phenotype at diagnosis.
Simultaneous treatment with ponatinib and blinatumomab was safe and effective in patients with newly diagnosed PH+ ALL.
The combination of decitabine/cedazuridine, venetoclax, and an IDH1 inhibitor was effective in treating IDH-mutated AML.
Ivosidenib and azacitidine led to deep and durable remissions associated with clearance of IDH1-mutated newly diagnosed AML.
The REALYSA study has garnered an enrollment rate of 54%—higher than typical clinical trial inclusion rates.
Selinexor plus ruxolitinib demonstrated promising clinical activity in patients with treatment-naïve myelofibrosis.
A new study presented at the 2022 ASH Annual Meeting identified causes of the increased myeloma risk in Black Americans.
The combination of interferon and ruxolitinib may be a treatment option for newly diagnosed polycythemia vera.
Momelotinib led to an increased likelihood of becoming transfusion-independent compared with danazol in myelofibrosis.
The VIALE-A trial showed a sustained OS benefit in patients with AML who received venetoclax and azacitidine,
Venetoclax plus HMAs led to higher response rates than non-venetoclax regimens in patients with newly diagnosed AML.
Courtney D. DiNardo, MD, MSCE, talks about mentorship and her research on hereditary cancer predisposition syndromes.
A recent case study found evidence of an acquired in utero mutation in monozygotic twins who presented with CALR.
A new prognostic model identified risk factors for reduced survival in patients with myelofibrosis who received ruxolitinib.
The EXPAND study supports the use of ruxolitinib 10 mg twice daily in patients with MF.
A large real-world study assessed patients who were diagnosed with myeloproliferative neoplasms before age 25.
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.